Skip to main content
OpenTrials

Clinical trial condition

Neurocutaneous Syndromes

Explore clinical trials studying Neurocutaneous Syndromes. Study availability and eligibility vary by location and protocol.

346 public trials 63 recruiting studies
Refine in advanced search Browse all conditions

Neurocutaneous Syndromes trial results

Active, Not Recruiting

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

NCT01089101

Conditions
Astrocytoma, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, +25 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
  • UCSF Medical Center-Mount Zion San Francisco, California, United States
  • UCSF Medical Center-Parnassus San Francisco, California, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

NCT03363217

Conditions
Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, +29 more
Locations
  • Alberta Children's Hospital Calgary, Alberta, Canada
  • Children and Women's Health Centre of British Colombia Vancouver, British Columbia, Canada
  • IWK Health Centre Halifax, Nova Scotia, Canada
  • The Hospital for Sick Children Toronto, Ontario, Canada
View Trial Details
Active, Not Recruiting

MElanoma Research Lymph Node Prediction Implementation National_001

NCT04759781

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cranial Nerve Diseases, Cranial Nerve Neoplasms, +30 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • Emory University School of Medicine Atlanta, Georgia, United States
  • University of Kentucky Lexington, Kentucky, United States
  • University of Louisville Louisville, Kentucky, United States
View Trial Details
Active, Not Recruiting

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

NCT03401788

Conditions
Abnormalities, Multiple, Angiomatosis, Cardiovascular Diseases, +14 more
Locations
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • University of Michigan Ann Arbor, Michigan, United States
  • University of Pennsylvania Medical Center Philadelphia, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

NCT02962414

Conditions
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, +17 more
Locations
  • TGen APNNA Phoenix, Arizona, United States
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • UCSF Benioff Children s Hospital Oakland, California, United States
  • Rady Children s Hospital San Diego, California, United States
View all 68 locations
View Trial Details
Active, Not Recruiting

Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

NCT06392009

Conditions
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Focal Cortical Dysplasia, +14 more
Locations
  • Queensland Children Hospital South Brisbane, Australia
  • University Hospitals Leuven, Pediatric Neurology Leuven, Belgium
  • Alberta Children's Hospital Calgary, Canada
  • The Hospital for Sick Children (Sick Kids) Toronto, Canada
View all 18 locations
View Trial Details

Related conditions